-
公开(公告)号：US09527921B2
公开(公告)日：2016-12-27
申请号：US15098869
申请日：2016-04-14
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: A61K39/395 , C07K16/32 , A61K33/24 , A61K31/47 , A61K31/337 , C07K16/28 , C07K16/30 , C07K14/705 , C07K14/71 , A61K39/00
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
Abstract translation: 本发明提供了可能对人Notch4具有中和活性的抗人Notch4抗体或Notch4结合片段，以及包含与活性成分相同的药物组合物。 本发明人获得了对人Notch4具有高中和活性和结合亲和力的小鼠抗人Notch4抗体，并确定了小鼠抗人Notch4抗体的互补决定区（CDR）序列。 这使得能够生产包含重链和轻链的可变区以及小鼠抗人Notch4抗体的CDR序列的人源化抗体。
-
公开(公告)号：US11725015B2
公开(公告)日：2023-08-15
申请号：US17167480
申请日：2021-02-04
Inventor： Yoshito Kishi , Kazunobu Kira , Ken Ito
IPC: C07D493/22 , A61P35/00 , A61K31/357 , A61K39/395 , C07K16/28 , A61K39/00
CPC classification number: C07D493/22 , A61K31/357 , A61K39/3955 , A61P35/00 , C07K16/2818 , C07K16/2863 , A61K2039/505 , A61K2300/00
Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.
-
公开(公告)号：US09969812B2
公开(公告)日：2018-05-15
申请号：US15382821
申请日：2016-12-19
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Yoshimasa Sakamoto , Yusuke Adachi , Junji Matsui , Yu Kato , Yoichi Ozawa , Takanori Abe , Ken Ito , Yuya Nakazawa , Sho Tachino , Katsuhisa Suzuki , Kishan Agarwala , Kana Hoshino , Masahiko Katayama
IPC: A61K39/395 , C07K16/28 , C07K16/30 , C07K14/705 , C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , C12N9/14 , C07K14/71 , A61K39/00
CPC classification number: C07K16/32 , A61K31/337 , A61K31/47 , A61K33/24 , A61K39/395 , A61K39/3955 , A61K39/39558 , A61K2039/505 , C07K14/705 , C07K14/71 , C07K16/28 , C07K16/2863 , C07K16/3023 , C07K16/303 , C07K2317/20 , C07K2317/24 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/21 , C07K2319/42 , C12N9/14 , C12Y301/03001 , A61K2300/00
Abstract: The present invention provides an anti-human Notch4 antibody or a Notch4 binding fragment thereof that may have neutralizing activity against human Notch4, as well as a pharmaceutical composition comprising the same as the active ingredient. The present inventors obtained a mouse anti-human Notch4 antibody that has high neutralizing activity and binding affinity towards human Notch4 and determined the complementarity determining region (CDR) sequence of the mouse anti-human Notch4 antibody. This enabled the production of a humanized antibody comprising the variable region of heavy and light chains as well as the CDR sequence of the mouse anti-human Notch4 antibody.
-
公开(公告)号：US20240309014A1
公开(公告)日：2024-09-19
申请号：US18480929
申请日：2023-10-04
Inventor： Yoshito Kishi , Kazunobu Kira , Ken Ito
IPC: C07D493/22 , A61P35/04
CPC classification number: C07D493/22 , A61P35/04
Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
-
公开(公告)号：US11407762B2
公开(公告)日：2022-08-09
申请号：US16764245
申请日：2018-11-15
Inventor： Yoshito Kishi , Kazunobu Kira , Ken Ito
IPC: C07D493/22 , A61P35/04
Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
-
Patent Agency Ranking
公开(公告)号：US09938288B1
公开(公告)日：2018-04-10
申请号：US15814105
申请日：2017-11-15
Inventor： Yoshito Kishi , Kazunobu Kira , Ken Ito
IPC: C07D498/22 , A61K31/357 , C07D493/22 , A61K39/395
CPC classification number: C07D493/22 , A61K31/357 , A61K39/3955 , A61K2300/00
Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
-
公开(公告)号：US20230406863A1
公开(公告)日：2023-12-21
申请号：US18339227
申请日：2023-06-21
Inventor： Yoshito Kishi , Kazunobu Kira , Ken Ito
IPC: C07D493/22 , A61P35/00 , A61K31/357 , A61K39/395 , C07K16/28
CPC classification number: C07D493/22 , A61P35/00 , A61K31/357 , A61K39/3955 , C07K16/2818 , C07K16/2863 , A61K2039/505
Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.
-
公开(公告)号：US11814398B2
公开(公告)日：2023-11-14
申请号：US17808418
申请日：2022-06-23
Inventor： Yoshito Kishi , Kazunobu Kira , Ken Ito
IPC: C07D493/22 , A61P35/04
CPC classification number: C07D493/22 , A61P35/04
Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
-
公开(公告)号：US20230016686A1
公开(公告)日：2023-01-19
申请号：US17808418
申请日：2022-06-23
Inventor： Yoshito Kishi , Kazunobu Kira , Ken Ito
IPC: C07D493/22 , A61P35/04
Abstract: The present invention provides novel compounds (e.g., compounds of Formulae (I), (II), (III), (IV)) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or pharmaceutically acceptable salts thereof, optionally in a pharmaceutically acceptable carrier, and a medical uses thereof.
-
公开(公告)号：US10954249B2
公开(公告)日：2021-03-23
申请号：US16500924
申请日：2018-04-03
Inventor： Yoshito Kishi , Kazunobu Kira , Ken Ito
IPC: C07D493/22 , A61K39/395 , A61K31/357 , C07K16/28 , A61P35/00 , A61K39/00
Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable and medical uses thereof.
-
-
-
-
-
-
-
-
-
Search Results
15
records
(took 0.022 seconds)
